Answers are grounded in this paper and cite their sources.
This review examines regulatory challenges and methodologies in AI-driven causal inference for drug development, highlighting implications for regulatory decisions.
Advances in AI offer significant opportunities to enhance drug development. While several regulatory agencies have begun issuing guidance on AI adoption, its application to causal inference—a critical piece to understand treatment effects and inform regulatory decisions—remains limited. This paper reviews regulatory activities and examines statistical methodologies for AI-driven causal inference. We discuss key regulatory challenges and illustrate how AI adds value across diverse data sources and studies.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: